Hua Liu, Steven A. Bigler, Jeffrey R. Henegar, Radhakrishna Baliga 

Slides:



Advertisements
Similar presentations
Volume 62, Pages S12-S22 (December 2002)
Advertisements

Volume 67, Issue 2, Pages (February 2005)
Volume 60, Issue 3, Pages (September 2001)
Cytochrome-P450 2B1 gene silencing attenuates puromycin aminonucleoside-induced cytotoxicity in glomerular epithelial cells  Niu Tian, Istvan Arany, David.
Volume 64, Issue 6, Pages (December 2003)
Volume 65, Issue 4, Pages (April 2004)
Volume 59, Issue 3, Pages (March 2001)
Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria  Dan Wang, Chunsun Dai, Yingjian Li, Youhua.
Volume 80, Issue 12, Pages (December 2011)
Volume 78, Issue 4, Pages (August 2010)
Inhibition of cytochrome P450 2E1 and activation of transcription factor Nrf2 are renoprotective in myoglobinuric acute kidney injury  Zhe Wang, Sudhir.
Volume 63, Issue 2, Pages (February 2003)
Volume 72, Issue 4, Pages (August 2007)
Volume 62, Issue 6, Pages (December 2002)
C.B. Marshall, J.W. Pippin, R.D. Krofft, S.J. Shankland 
Characterization of proteinuria and tubular protein uptake in a new model of oral L-lysine administration in rats  K. Thelle, E.I. Christensen, H. Vorum,
Volume 60, Issue 2, Pages (August 2001)
Volume 61, Issue 5, Pages (May 2002)
Volume 56, Issue 1, Pages (July 1999)
Volume 58, Issue 6, Pages (December 2000)
Volume 54, Issue 5, Pages (November 1998)
Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis  Hua Liu, Radhakrishna Baliga  Kidney International 
Volume 63, Issue 4, Pages (April 2003)
Volume 63, Issue 1, Pages (January 2003)
Volume 59, Issue 4, Pages (April 2001)
Volume 56, Issue 6, Pages (December 1999)
Volume 59, Issue 1, Pages (January 2001)
Volume 60, Issue 3, Pages (September 2001)
Volume 59, Issue 5, Pages (May 2001)
Volume 64, Issue 2, Pages (August 2003)
Volume 60, Issue 3, Pages (September 2001)
Oliver Vonend, Clare M. Turner  Kidney International 
Volume 67, Issue 5, Pages (May 2005)
Volume 63, Issue 2, Pages (February 2003)
Volume 60, Issue 6, Pages (December 2001)
Volume 67, Issue 2, Pages (February 2005)
Volume 74, Issue 5, Pages (September 2008)
Hai Tao Yuan, Su Ping Yang, Adrian Spencer Woolf  Kidney International 
Cytochrome-P450 2B1 gene silencing attenuates puromycin aminonucleoside-induced cytotoxicity in glomerular epithelial cells  Niu Tian, Istvan Arany, David.
Volume 61, Issue 6, Pages (June 2002)
Volume 56, Issue 3, Pages (September 1999)
Volume 72, Issue 3, Pages (August 2007)
Volume 68, Issue 6, Pages (December 2005)
Volume 71, Issue 7, Pages (April 2007)
Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis  M. Hagiwara, K. Yamagata, R.A. Capaldi, A. Koyama 
Volume 62, Issue 5, Pages (November 2002)
C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis  Gopala K. Rangan, Jeffrey W. Pippin, William.
Volume 62, Pages S12-S22 (December 2002)
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 80, Issue 5, Pages (September 2011)
Hideyuki Murakami, Katsutoshi Yayama, Lee Chao, Julie Chao 
Volume 69, Issue 11, Pages (June 2006)
Small heat shock protein alteration provides a mechanism to reduce mesangial cell contractility in diabetes and oxidative stress  Marjorie E. Dunlop,
Kaihui Liang, Nosratola D. Vaziri  Kidney International 
MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis  Sang-Kyung Jo, Won Yong Cho, Su Ah Sung, Hyoung.
Volume 65, Issue 6, Pages (June 2004)
Volume 64, Issue 3, Pages (September 2003)
Protective effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on glomerular protein permeability barrier  Ellen T. Mccarthy, R.A.M. Sharma, Mukut Sharma,
Barbara A. Bresnahan, Shelly Dufek, Shenghua Wu, Elias A. Lianos, M.D. 
Volume 59, Issue 5, Pages (May 2001)
Volume 56, Issue 6, Pages (December 1999)
Volume 63, Issue 1, Pages (January 2003)
Volume 57, Issue 4, Pages (April 2000)
Volume 58, Issue 3, Pages (September 2000)
IL-1β induces VEGF, independently of PGE2 induction, mainly through the PI3-K/mTOR pathway in renal mesangial cells  D. Solà-Villà, M. Camacho, R. Solà,
Volume 55, Issue 4, Pages (April 1999)
T-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis  Masashi Haraguchi, Wayne A. Border, Yufeng Huang,
Volume 60, Issue 3, Pages (September 2001)
Volume 68, Issue 1, Pages (July 2005)
Volume 65, Issue 1, Pages (January 2004)
Presentation transcript:

Cytochrome P450 2B1 mediates oxidant injury in puromycin-induced nephrotic syndrome  Hua Liu, Steven A. Bigler, Jeffrey R. Henegar, Radhakrishna Baliga  Kidney International  Volume 62, Issue 3, Pages 868-876 (September 2002) DOI: 10.1046/j.1523-1755.2002.00515.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 Hypothesis. Kidney International 2002 62, 868-876DOI: (10.1046/j.1523-1755.2002.00515.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 2 Identification and localization of CYP2B1 in the rat kidney. (A) Immunohistochemistry, (B) Western blot and (C) specific CYP2B1 activity indicate that CYP2B1 is present in the glomeruli but not in the tubules. Kidney International 2002 62, 868-876DOI: (10.1046/j.1523-1755.2002.00515.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 3 (A) Effect of cytochrome P450 (CYP) inhibitors on the proteinuria (mg/24 h urine) in rats treated with puromycin aminonucleoside (PAN). Symbols are: (•) control, N = 6; (·) PAN, N = 10; (▾) CM, N = 6; (▪) PIP, N = 8. (B) Effect of CYP inhibitors on the serum albumin (g/dL) in rats treated with PAN. Values are means ± SE, N = 6 to 10. *P < 0.05 compared with the rats treated with PAN alone. +P < 0.05 compared with the control rats. Kidney International 2002 62, 868-876DOI: (10.1046/j.1523-1755.2002.00515.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 4 Localization of H2O2 by a histochemical cerium-H2O2 precipitation method in rat kidney 6 hours after PAN injection. (A) Control animals did not show any reaction product. (B) PAN treated rats demonstrated electron dense granular cerium-precipitation reaction product in the glomerular capillary basement membrane. (C) The cerium-H2O2 precipitation in the glomerular basement membrane was significantly reduced in the rats treated with the CYP2B1 inhibitor PIP. (D) Rat glomeruli showed marked fusion of podocyte foot processes 4 days after PAN injection (E). Treatment with PIP prevented the PAN-induced fusion of the foot processes (magnification ×15,000). Kidney International 2002 62, 868-876DOI: (10.1046/j.1523-1755.2002.00515.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 5 Effect of CYP inhibitors on the bleomycin detectable iron content in the glomeruli of PAN treated rats. Values are means ± SE, N = 3 to 5, *P < 0.05 compared with control rats, +P < 0.05 compared with the rats treated with PAN alone. Kidney International 2002 62, 868-876DOI: (10.1046/j.1523-1755.2002.00515.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 6 Immunohistochemistry studies of rat renal cortex. The first column shows representative photographs using primary antibodies to CYP2B1 in animals injected with saline, versus animals injected with PAN at 6 hours post-injection, at 4 days post-injection, and in animals that have been treated with piperine or cimetidine at 6 hours after PAN injection. The second column shows the same animals studied with primary antibodies to heme oxygenase. The third column shows the same animals studied with primary antibodies to ferritin. Note that CYP2B1 is expressed in the saline injected rat and in the rat with piperine or cimetidine treatment, but is absent in the glomerulus 6 hours after PAN injection, and decreased at 4 days after injection. Both heme oxygenase and ferritin are virtually absent in the saline injected animal, but highly expressed in glomeruli and tubular epithelium following PAN injection at 6 hours and 4 days, with decreased levels of expression in the animals treated with piperine and cimetidine. Kidney International 2002 62, 868-876DOI: (10.1046/j.1523-1755.2002.00515.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 7 Western blot analysis of CYP2B1 protein in the glomeruli of rats injected with PAN with or without administration of CYP inhibitors CM and PIP. The blots are representative of results from six to ten animals per experimental group at 6 hours and 7 days after PAN injection. Kidney International 2002 62, 868-876DOI: (10.1046/j.1523-1755.2002.00515.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 8 Western blot analysis of HO-1 protein in the glomeruli of rats injected with PAN with or without administration of CYP inhibitors CM and PIP. Blots are representative of results from six to ten animals per experimental group at 6 hours and 7 days after PAN injection. Kidney International 2002 62, 868-876DOI: (10.1046/j.1523-1755.2002.00515.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 9 Induction of HO-1 mRNA in the kidney of PAN treated rats and the effect of CYP2B1 inhibitor piperine (PIP) on this induction. (A) Agarose gel (2%) electrophoresis of RT-PCR products of HO-1 mRNA and GAPDH mRNA (amplified at the same time for the internal standard). (B) OD values for HO-1 mRNA at each time point are expressed compared with the values for GAPDH. HO-1 mRNA expression in the kidney was significantly increased at one hour after PAN injection and continued to increase until day 4. Administration of CYP2B1 inhibitor piperine markedly reduced the induction of HO-1 mRNA at each time point. The OD values are means ± SE, N = 3, P < 0.05 compared with control level. Kidney International 2002 62, 868-876DOI: (10.1046/j.1523-1755.2002.00515.x) Copyright © 2002 International Society of Nephrology Terms and Conditions